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The objective of this retrospective study was to determine the efficacy of adjuvant hysterectomy for treatment of residual disease in
cervical carcinoma treated with radiation therapy. Between 1971 and 1996, 1590 patients with carcinoma of the uterine cervix
(stages I–IIIb) were treated with radiation therapy. Three months after completion of radiation therapy, the status of local control
was investigated, and total abdominal hysterectomy was performed in cases in which central residual disease existed in the cervix. Of
the 1590 patients, residual disease was identified in 162 patients. Among these patients, 35 showed an absence of distant metastasis
or lateral parametrial invasion and underwent hysterectomy. The overall 5- and 10-year survival rates for these patients were 68.6
and 65.7%, respectively. There was no significant difference in survival between patients with squamous cell carcinoma and those with
non-squamous cell carcinoma or between patients with stage I/II carcinoma and those with stage III carcinoma. With respect to
treatment-related morbidity, five (14.3%) patients suffered grade III or IV complications after hysterectomy. Adjuvant hysterectomy is
an effective addition to radiation therapy in the treatment of cervical cancer, even in patients with stage III disease and in those with
non-squamous cell carcinoma.
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Cervical cancer is one of the most common cancers in women
worldwide. Annually, it is estimated that 493000 women world-
wide will be diagnosed with cervical carcinoma and that 273000
will die from the disease (Parkin et al, 2005). Traditionally, radical
hysterectomy or radiation therapy alone has been accepted as
standard treatment for early-stage invasive cervical cancer, and
locally advanced cancer has been treated by radiation therapy
alone, consisting of a combination of high-dose-rate intracavitary
brachytherapy (ICBT) and external beam radiation therapy
(EBRT) (Coia et al, 1990; Komaki et al, 1995; Barillot et al,
1997). In the last few years, substantial advances in the manage-
ment of locally advanced cervical cancer have been reported. Five
randomised trials have shown improved survival and local control
when cisplatin-based chemotherapy is performed concurrently
with radiation therapy in patients with locally advanced cervical
cancer (Keys et al, 1999; Morris et al, 1999; Rose et al, 1999;
Whitney et al, 1999; Peters et al, 2000). This combined modality
approach produced an absolute increase in 5-year survival of 12%
compared with radiation therapy alone and has resulted in a
dramatic change in the standard of care for this disease.
Although the general prognosis of patients with cervical cancer
treated with radiation therapy has improved, how to best treat
patients with residual disease after radiation therapy remains
controversial. These patients have been considered to have an
extremely poor prognosis (Moore et al, 2004; Long et al, 2005). The
value of surgical treatment for such patients has been investigated,
but in most of these studies, extended surgery, such as radical
hysterectomy or pelvic exenteration, was performed, resulting in a
high rate of severe treatment-related morbidity and decreased
quality of life. For more than 30 years, we have performed simple
abdominal hysterectomy in patients with residual disease identi-
fied 3 months after the completion of radiation therapy if the
residual disease is central, without distant metastasis. The present
study evaluated the treatment results of 35 cases who underwent
so-called ‘adjuvant hysterectomy’ after radiation therapy.
METHODS
During the period 1971 through 1996, a total of 1590 new patients
with primary invasive cervical carcinoma were treated by radiation
therapy alone at the Cancer Institute Hospital, Tokyo, Japan.
Disease stages were as follows: Ib, 197 patients; IIa, 29 patients; IIb,
620 patients; IIIa, 18 patients; and IIIb, 726 patients. Staging was
performed according to the International Federation of Gynecol-
ogy and Obstetrics criteria. A combination of EBRT and ICBT was
used in all patients. The regimen for radiation therapy is described
elsewhere (Ota et al, 2007). In brief, EBRT of a total dose of 50Gy
was delivered at 2Gy per day, 5 days a week for 5 weeks. High-
dose-rate remote after loading ICBT was also performed. A dose of
4Gy was administered 2 or 3 times per week for a total of 40Gy.
Three months after the completion of radiation therapy, the
status of local control was investigated. Simple hysterectomy (class
I hysterectomy) (Piver et al, 1974) was performed predominantly
in incidence of patients with central residual disease within 2
months of discovery. The local control in response to radiation
therapy and the number of patients who underwent subsequent
hysterectomy are shown in Figure 1. Of the 1590 patients, 1428 Received 14 April 2008; revised 22 July 2008; accepted 27 July 2008
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sexperienced a complete response, as shown by cytologic and
histologic assessment. Of 162 patients with persistent local disease,
35 underwent hysterectomy. The other 127 patients did not
undergo surgery because of the presence of concomitant distant
metastasis (n¼26) or because of advanced age, poor medical
condition, or refusal of surgery (n¼101).
Follow-up examinations were performed every 3 months during
the first 5 years after treatment and then at 6-month intervals for
the next 5 years. All follow-up examinations included pelvic
examination with cytologic assessment of the uterine cervix and
tumour marker SCC antigen, and identification late complications.
Every 6 months, we obtained CT scan of the abdomen and chest
X-ray were performed. All patients were followed up for more than
10 years after radiation therapy. Our hospital is one of the few
institutions permitted access to the family registry database. We
consulted the district legal affairs bureau for survival information
or the cause of death for each patient; none of the patients was lost
to follow-up. Of the 1590 patients, 1323 (83.2%) were followed-up
directly at the hospital, and 267 (16.8%) were followed-up through
the district legal affairs bureau.
The survival data for each patient was calculated from the date
therapy was started to the date of the latest follow-up examination.
Survival curves were drawn according to the Kaplan–Meier
method. The log-rank test was used for univariate analysis.
P values less than 0.05 were considered statistically significant.
With respect to radiation-related morbidity, late rectal and
bladder complications and non-rectal gastrointestinal sequelae
(small-bowel complications) were graded according to the RTOG/
EORTC scoring system (Cox et al, 1995).
RESULTS
Study population
The numbers of patients who underwent hysterectomy, listed by
initial stage and cell type, are shown in Table 1. The mean age was
55.7 years (range, 36–74 years). Of the 35 patients, the number of
patients with squamous cell carcinoma stage Ib, IIb, or IIIb were 3,
12, and 13, respectively, and the numbers with non-squamous cell
carcinoma stage Ib, IIb, or IIIb disease were 1, 4, and 2.
Hysterectomy
Details of the hysterectomy procedures are listed in Table 2. Type I
hysterectomy was performed in 32 patients, and type III radical
hysterectomy was performed in three patients; none of the patient
underwent pelvic or para-aortic lymphadenectomy (Piver et al,
1974). The duration of surgery type for type I and type III
hysterectomy was 95.6±34.1 and 158.0±32.9min, respectively.
Blood loss was 457.6±362.3 and 590.0±101.5ml, respectively.
Four patients showed residual disease after type I hysterectomy,
and none of the patients showed residual disease after type III
radical hysterectomy. Two of the four patients with residual
disease, two underwent chemotherapy, and the other two under-
went palliative treatment after hysterectomy. Thus, there were 31
patients with no residual disease after hysterectomy. However,
recurrence developed in eight: local recurrence in four and distant
recurrence in four.
Survival
Disease-specific survival for the 35 patients who underwent
hysterectomy is shown in Figure 2. The 5- and 10-year survival
rates in this group were 68.6 and 65.7%, respectively. Clinical
outcomes of patients who did not undergo hysterectomy, with or
without distant metastasis, are also shown in Figure 2. Disease-
specific 5-year survival rates for patients who did not undergo
hysterectomy despite the absence of distant metastasis and those
Total
1590
Residual disease
162
Complete response
1428
Hysterectomy
35
No hysterectomy
127
Figure 1 Incidence of local control in response to radiation therapy
(complete response) and number of patients who underwent subsequent
hysterectomy because of residual disease.
Table 1 Case of cervical carcinoma treated with hysterectomy after
radiation therapy
Clinical stage Number of patients
Squamous cell carcinoma
Stage Ib 3
Stage IIb 12
Stage IIIb 13
Non-squamous cell carcinoma
Stage Ib 1
Stage IIb 4
Stage IIIb 2
Total 35
Table 2 Hysterectomy
Type I hysterectomy (n¼32)
Duration of surgery 95.6±34.1min
Blood loss 457.6±362.3ml
Residual disease 4 patients
Type III radical hysterectomy (n¼3)
Duration of surgery 158.0±32.9min
Blood loss 590.0±101.5ml
Residual disease 0 patients
P=0.0001
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Figure 2 Disease-specific survival according to treatment methods and
the presence or absence of distant metastasis for patients with cervical
carcinoma. Hyst¼Hysterectomy.
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swith concomitant distant metastasis were 14.5 and 0%, respec-
tively. Significant differences were noted between the three groups
(P¼0.0001). Disease-specific survival curves are shown according
to cancer stage in Figure 3. The cumulative 5-year survival rates for
initial stages Ib, IIb, and IIIb disease were 100, 73.3, and 56.3%,
respectively, and 10-year survival rates for initial stages Ib, IIb, and
IIIb disease were 100, 66.7, and 56.3%, respectively. Disease-
specific survival curves are shown according to histologic type in
Figure 4. The 5- and 10-year survival rates for patients with
squamous cell carcinoma were 74.1 and 70.4%, respectively, and
those for patients with non-squamous cell carcinoma were both
57.1%. No difference was observed in survival between patients
with squamous cell carcinoma and those with non-squamous cell
carcinoma (P¼0.6862). Disease-specific survival curves are shown
according to tumour size in Figure 5. The size of the persistent
tumour at the time of hysterectomy was important with respect to
survival. The 5- and 10-year survival rates for patients with lesions
less than 2cm in diameter were both 75.0% and those for patients
with larger lesions were 54.4 and 45.5%, respectively. There was a
trend for better survival of smaller tumours compared with larger
tumours, but this difference was not statistically significant
(P¼0.053).
Postoperative complications
One patient who suffered postoperative small-bowel obstruction
was treated conservatively, and was discharged 40 days after
surgery. Six patients (17.1%) experienced pelvic or urinary tract
infection, but none required surgical intervention. No treatment-
related deaths occurred.
Late complications
Late complications are listed in Table 3. According to the RTOG/
EORTC scoring system, grade III or IV late complications
involving the rectum, small-bowel, or urinary tract were observed
in five (14.3%) cases, three were stage II and two were stage III.
The incidences of grade III and grade IV rectal complications were
0 and 2.9% (one patient), respectively. None of the patients
experienced grade III or grade IV small-bowel complications. The
incidences of grade III and grade IV urinary tract complications
were 2.9% (one patient) and 5.7% (two patients), respectively. One
patient (stage III disease) required reconstruction of both the
urinary tract and lower gastrointestinal tract.
DISCUSSION
There is no standard treatment for residual cervical carcinoma in
cases in which radiation therapy is insufficient. Patients with
residual disease often undergo chemotherapy, with only minor
palliation and without any significant improvement in survival
(Moore et al, 2004; Long et al, 2005). Other treatments include re-
irradiation or interstitial irradiation offering local control rates of
64–92% along with a 5-year survival rate of 4–44% for recurrent
cervical cancer. However, a high rate of severe complications has
been reported in both the urinary and lower gastrointestinal tracts
(Russell et al, 1987; Sommers et al, 1989; Xiang-E et al, 1998).
With respect to surgical treatment for residual disease after
radiation therapy, the most effective method is probably pelvic
exenteration (Stanhope et al, 1990). Total pelvic exenteration offers
a 5-year survival rate of 23–50%, but it requires alterations of both
the urinary and lower gastrointestinal tracts, and a high rate of
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Figure 3 Disease-specific survival according to clinical stage for patients
with cervical carcinoma.
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Figure 4 Disease-specific survival according to histologic type for
patients with cervical carcinoma.
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Figure 5 Disease-specific survival according to tumour size for patients
with cervical carcinoma.
Table 3 Grades of late complications according to site
Grade III (%) Grade IV (%) Grade V (fatal)
Rectum — 1 (2.9) —
Small bowel — — —
Bladder 1 (2.9) 2 (5.7) —
Combined — 1 (2.9) —
Total 1 (2.9) 4 (11.4) —
Total: Five cases (14.3%).
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ssevere postoperative complications, such as infection, injury of
the urinary and lower gastrointestinal tracts, and small-bowel
obstruction, occur, in addition to a 4–14% surgery-related
mortality rate (Rutledge et al, 1977; Morley et al, 1989; Shingleton
et al, 1989; Matthews et al, 1992; Moutardier et al, 2004).
The utility of radical hysterectomy, a more conservative
procedure, has been reported, but it also has a high rate of
complications. Coleman et al (1994) evaluated the utility of radical
hysterectomy (chiefly type III hysterectomy) including pelvic
lymphadenectomy in 50 patients with persistent or recurrent
cervical cancer after primary radiation therapy. The 5- and 10-year
survival rates for all cases was 72 and 60%, but severe post-
operative complications (grade III or higher) occurred in 42%
of the patients, along with one postoperative death because of
sepsis. The most common site of injury was the urinary tract,
with 14 patients (28%) developing vesicovaginal fistula, 11 (22%)
developing ureteral injuries, and 10 (20%) developing severe long-
term bladder dysfunction. Maneo et al (1999) evaluated the utility
of type III radical hysterectomy including pelvic lymphadenectomy
in 34 patients with persistent or recurrent cervical cancer after
primary radiation therapy. The 5-year survival rate for all cases
was 49%. No treatment-related deaths or early postoperative
complications occurred, but 18 major complications occurred in
15 (44%) of the patients. Rutledge et al (1994) studied 47 patients
with persistent or recurrent cervical cancer after primary radiation
therapy and reported that radical hysterectomy resulted in major
complications in 20 (42.4%) of the patients, including two
treatment-related deaths. These results suggest that radical
hysterectomy including pelvic lymphadenectomy can be an
alternative to exenteration, but the high incidence of treatment-
related morbidity remains a major issue.
The necessity of lymphadenectomy in recurrent or persistent
disease should be addressed. Coleman et al (1994) reported that all
five patients with positive nodes died of cancer, whereas 14 of 34
patients (41.2%) with negative nodes died of cancer (P¼0.02).
Maneo et al, (1999) identified six node-positive patients in their
series, and five experienced recurrence, whereas half of 28 node-
negative patients experienced recurrence. Thus, it is likely that
pelvic lymphadenectomy resulted in little, if any, improvement of
survival in residual disease after radiation therapy. Results of the
present study, along with these previous studies, suggest that
abdominal simple hysterectomy without pelvic lymphadenectomy
(class II hysterectomy) may be sufficient in eliminating residual
disease after radiation therapy.
The value of adjuvant hysterectomy in the treatment of cervical
cancer after radiation therapy has been investigated; most of these
studies suggest a decreased incidence of local relapse but no
benefit in progression-free survival (Perez et al, 1987; Keys et al,
2003). Keys et al (2003) reported in a Gynecologic Oncology Group
trial that performing adjuvant hysterectomy in every case of
cervical cancer after radiation therapy is of little value in
improving survival, although no significant increase in treat-
ment-related morbidity is observed. In addition, Whitney et al
(1999) reported that 7 of 30 (23.3%) stage IB patients with residual
disease showed recurrence, whereas only 1 of 50 patients (2%)
showed recurrence in the absence of evidence of persistent residual
disease. Gallion et al (1985) reported similar results, with 5 of 14
(35.7%) residual disease showing recurrence compared to 2 of 29
(6.9%) with no residual disease. Thus, our belief is that adjuvant
hysterectomy should be performed only in cases of residual disease
of the cervix and that surgical treatment is unnecessary in cases
with no residual disease.
It is noteworthy that adjuvant hysterectomy for residual disease
after radiation therapy can be applied for patients with non-
squamous cell carcinoma or stage III disease. Previous reports
suggest that adenocarcinoma of the cervix has a poor prognosis
(Eifel et al, 1990). Nakano et al (1995) report resulted of 58 patients
with adenocarcinoma of the cervix treated with radiation. The local
control rates in stage III and stage IV cases were 56 and 27%,
respectively, and 5-year survival rates were 32.3 and 9.1%. These
findings suggest that patients with adenocarcinoma who have
residual disease as a failure of radiation therapy often have a poor
prognosis in the absence of appropriate treatment for the residual
disease. Gerdin et al (1994) performed radiation therapy and
adjuvant hysterectomy in all of their cases, and reported successful
results in the treatment of non-squamous cervical cancer and that
the histologic tumour type is not a significant prognostic factor. In
the present study, we also found no significant difference in the
survival between patients with squamous cell carcinoma and those
with non-squamous cell carcinoma.
Residual stage III disease is seldom treated surgically. The
present study showed 5- and 10-year survival rates for patients
with stage III disease of 56.3%, with acceptable treatment-related
morbidity, suggesting that adjuvant hysterectomy may be of value
in the treatment of advanced cervical cancer.
Previous studies have reported a correlation between tumour
size at surgery and survival rate. Coleman et al (1994) reported
that tumour size at surgery is significantly associated with survival.
The 5-year survival rate for the 12 of 44 patients (27.3%) with
lesion diameter less than 2cm was 90% compared with 64% in
patients with larger lesions (Po0.01). Maneo et al (1999) also
reported that smaller tumour size (o4cm) in recurrent disease is
predictive of survival. In the present study, there was a trend for
better survival smaller-sized tumours (o2cm) compared with
those with larger-sized tumours.
In conclusion, adjuvant hysterectomy is a viable option when
applied to patients in whom an incomplete response to radiation
leaves residual cervical carcinoma. This treatment is also effective
in patients with stage III disease and in those with non-squamous
cell carcinoma.
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